The Hypercoagulable State in Thalassemia Intermedia

REFERENCES

• Galanello R, Cao A. Relationship between genotype and phenotype. Thalassemia intermedia. Ann NY Acad Sci. 1998;850:325–333.
   PubMed Web of Science ®Google Scholar
• Weatherall D. The molecular basis for phenotypic variability of the common thalassaemias. Mol Med Today. 1995;1:15–20.
   PubMedGoogle Scholar
• Taher A, Ismaeel H, Cappellini MD. Thalassaemia intermedia: revisited. Blood Cells Mol Dis. 2006;37:12–20.
   PubMed Web of Science ®Google Scholar
• Olivieri NF. The beta-thalassemias. N Engl J Med. 1999;341:99–109.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A. Guidelines for the Clinical Management of Thalassaemia. 2nd Revised ed. NicosiaCyprus: Thalassaemia International Federation; 2008.
   Google Scholar
• Taher A, Abou-Mourad Y, Abchee A, Zallouaa P, Shamseddine A. Pulmonary thromboembolism in beta-thalassemia intermedia: are we aware of this complication? Hemoglobin. 2002;26:107–112.
   PubMed Web of Science ®Google Scholar
• Taher AT, Otrock ZK, Uthman I, Cappellini MD. Thalassemia and hypercoagulability. Blood Rev. 2008;22:283–292.
   PubMed Web of Science ®Google Scholar
• Michaeli J, Mittelman M, Grisaru D, Rachmilewitz EA. Thromboembolic complications in beta thalassemia major. Acta Haematol. 1992;87:71–74.
   PubMed Web of Science ®Google Scholar
• Aessopos A, Farmakis D, Karagiorga M, Rombos I, Loucopoulos D. Pseudoxanthoma elasticum lesions and cardiac complications as contributing factors for strokes in betathalassemia patients. Stroke. 1997;28:2421–2424.
   Google Scholar
• Moratelli S, De Sanctis V, Gemmati D, et al. Thrombotic risk in thalassemic patients. J Pediatr Endocrinol Metab. 1998;11(3):915–921.
   Google Scholar
• Borgna Pignatti C, Carnelli V, Caruso V, et al. Thromboembolic events in beta thalassemia major: an Italian multicenter study. Acta Haematol. 1998;99:76–79.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli AP, Mannucci AP. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol. 2000;111:467–473.
   PubMed Web of Science ®Google Scholar
• Taher A, Isma'eel H, Mehio G, et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost. 2006;96:488–491.
   PubMed Web of Science ®Google Scholar
• Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet. 1989;2:27–30.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187–1193.
   PubMed Web of Science ®Google Scholar
• Manfre L, Giarratano E, Maggio A, Banco A, Vaccaro G, Lagalla R. MR imaging of the brain: findings in asymptomatic patients with thalassemia intermedia and sickle cell-thalassemia disease. AJR Am J Roentgenol. 1999;173:1477–1480.
   PubMed Web of Science ®Google Scholar
• Logothetis J, Constantoulakis M, Economidou J, et al. Thalassemia major (homozygous beta-thalassemia). A survey of 138 cases with emphasis on neurologic and muscular aspects. Neurology. 1972;22:294–304.
   PubMed Web of Science ®Google Scholar
• Gillis S, Cappellini MD, Goldfarb A, Ciceri L, Fiorelli G, Rachmilewitz EA. Pulmonary thromboembolism in thalassemia intermedia patients. Haematologica. 1999;84:959–960.
   Google Scholar
• van Teunenbroek A, Wijburg FA, ten Cate JW, van den Berg RS, Weening RS. Thromboembolic complications in an asplenic HbE-beta-thalassaemia patient. Neth J Med. 1989;35:123–127.
   Google Scholar
• Sonakul D, Pacharee P, Laohapand T, Fucharoen S, Wasi P. Pulmonary artery obstruction in thalassaemia. Southeast Asian J Trop Med Public Health. 1980;11:516–523.
   PubMedGoogle Scholar
• Sumiyoshi A, Thakerngpol K, Sonakul D. Pulmonary microthromboemboli in thalassemic cases. Southeast Asian J Trop Med Public Health. 1992;23(2):29–31 Suppl..
   Google Scholar
• Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood. 2002;99:36–43.
   PubMed Web of Science ®Google Scholar
• Cappellini MD. Coagulation in the pathophysiology of hemolytic anemias. Hematology Am Soc Hematol Educ Program 2007; 74–78.
   Google Scholar
• Ataga KI, Cappellini MD, Rachmilewitz EA. Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br J Haematol. 2007;139:3–13.
   PubMed Web of Science ®Google Scholar
• Winichagoon P, Fucharoen S, Wasi P. Increased circulating platelet aggregates in thalassaemia. Southeast Asian J Trop Med Public Health. 1981;12:556–560.
   PubMedGoogle Scholar
• Del Principe D, Menichelli A, Di Giulio S, De Matteis W, Cianciulli P, Papa G. PADGEM/GMP-140 expression on platelet membranes from homozygous beta thalassaemic patients. Br J Haematol. 1993;84:111–117.
   PubMed Web of Science ®Google Scholar
• Ruf A, Pick M, Deutsch V, et al. In-vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with beta-thalassaemia major. Br J Haematol. 1997;98:51–56.
   PubMed Web of Science ®Google Scholar
• Eldor A, Krausz Y, Atlan H, et al. Platelet survival in patients with beta-thalassemia. Am J Hematol. 1989;32:94–99.
   PubMed Web of Science ®Google Scholar
• Eldor A, Lellouche F, Goldfarb A, Rachmilewitz EA, Maclouf J. In vivo platelet activation in beta-thalassemia major reflected by increased platelet-thromboxane urinary metabolites. Blood. 1991;77:1749–1753.
   PubMed Web of Science ®Google Scholar
• Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med. 2005;353:1135–1146.
   PubMed Web of Science ®Google Scholar
• Shinar E, Rachmilewitz EA, Lux SE. Differing erythrocyte membrane skeletal protein defects in alpha and beta thalassemia. J Clin Invest. 1989;83:404–410.
   PubMed Web of Science ®Google Scholar
• Hershko C, Graham G, Bates GW, Rachmilewitz EA. Nonspecific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol. 1978;40:255–263.
   PubMed Web of Science ®Google Scholar
• Kuypers FA, de Jong K. The role of phosphatidylserine in recognition and removal of erythrocytes. Cell Mol Biol (Noisy-le-grand). 2004;50:147–158.
   PubMed Web of Science ®Google Scholar
• Tavazzi D, Duca L, Graziadei G, Comino A, Fiorelli G, Cappellini MD. Membrane-bound iron contributes to oxidative damage of beta-thalassaemia intermedia erythrocytes. Br J Haematol. 2001;112:48–50.
   PubMed Web of Science ®Google Scholar
• Borenstain-Ben Yashar V, Barenholz Y, Hy-Am E, Rachmilewitz EA, Eldor A. Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am J Hematol. 1993;44:63–65.
   PubMed Web of Science ®Google Scholar
• Helley D, Eldor A, Girot R, Ducrocq R, Guillin MC, Bezeaud A. Increased procoagulant activity of red blood cells from patients with homozygous sickle cell disease and betathalassemia. Thromb Haemost. 1996;76:322–327.
   PubMed Web of Science ®Google Scholar
• Atichartakarn V, Angchaisuksiri P, Aryurachai K, et al. Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/beta thalassaemic patients. Br J Haematol. 2002;118:893–898.
   PubMed Web of Science ®Google Scholar
• Chen S, Eldor A, Barshtein G, et al. Enhanced aggregability of red blood cells of beta-thalassemia major patients. Am J Physiol. 1996;270:H1951–H1956.
   PubMedGoogle Scholar
• Butthep P, Bunyaratvej A, Funahara Y, et al. Alterations in vascular endothelial cellrelated plasma proteins in thalassaemic patients and their correlation with clinical symptoms. Thromb Haemost. 1995;74:1045–1049.
   PubMed Web of Science ®Google Scholar
• Butthep P, Bunyaratvej A, Funahara Y, et al. Possible evidence of endothelial cell activation and disturbance in thalassemia: an in vitro study. Southeast Asian J Trop Med Public Health. 1997;28(Suppl. 3):141A–148A.
   PubMedGoogle Scholar
• Hovav T, Goldfarb A, Artmann G, Yedgar S, Barshtein G. Enhanced adherence of beta-thalassaemic erythrocytes to endothelial cells. Br J Haematol. 1999;106:178–181.
   PubMed Web of Science ®Google Scholar
• Butthep P, Rummavas S, Wisedpanichkij R, Jindadamrongwech S, Fucharoen S, Bunyaratvej A. Increased circulating activated endothelial cells, vascular endothelial growth factor, and tumor necrosis factor in thalassemia. Am J Hematol. 2002;70:100–106.
   PubMed Web of Science ®Google Scholar
• Carlos TM, Harlan J M. Leukocyte-endothelial adhesion molecules. Blood. 1994;84:2068–2101.
   PubMed Web of Science ®Google Scholar
• Mann KG, van't Veer C, Cawthern K, Butenas S. The role of the tissue factor pathway in initiation of coagulation. Blood Coagul Fibrinolysis. 1998;9(Suppl. 1):S3–S7.
   Google Scholar
• Habib A, Kunzelmann C, Shamseddeen W, Zobairi F, Freyssinet JM, Taher A. Elevated levels of circulating procoagulant microparticles in patients with b-thalassemia Intermedia. Haematologica. 2008;93:941–942.
   PubMedGoogle Scholar
• Cappellini MD, Grespi E, Cassinerio E, Bignamini D, Fiorelli G. Coagulation and splenectomy: an overview. Ann NY Acad Sci. 2005;1054:317–324.
   PubMed Web of Science ®Google Scholar
• Atichartakarn V, Angchaisuksiri P, Aryurachai K, Chuncharunee S, Thakkinstian A. In vivo platelet activation and hyperaggregation in hemoglobin E/beta-thalassemia: a consequence of splenectomy. Int J Hematol. 2003;77:299–303.
   PubMed Web of Science ®Google Scholar
• Zalloua PA, Shbaklo H, Mourad YA, Koussa S, Taher A. Incidence of thromboembolic events in Lebanese thalassemia intermedia patients. Thromb Haemost. 2003;89:767–768.
   PubMed Web of Science ®Google Scholar
• Iolascon A, Giordano P, Storelli S, et al. Thrombophilia in thalassemia major patients: analysis of genetic predisposing factors. Haematologica. 2001;86:1112–1113.
   PubMed Web of Science ®Google Scholar
• Giordano P, Galli M, Del Vecchio GC, et al. Lupus anticoagulant, anticardiolipin antibodies and hepatitis C virus infection in thalassaemia. Br J Haematol. 1998;102:903–906.
   PubMed Web of Science ®Google Scholar
• Saunthararajah Y, Hillery CA, Lavelle D, et al. Effects of 5-aza-2¢-deoxycytidine on fetal haemoglobin levels, red cell adhesion, and haematopoietic differentiation in patients with sickle cell disease. Blood. 2003;102:3865–3870.
   PubMed Web of Science ®Google Scholar
• Covas DT, Angulo I, Palma PVB, Zago M A. Effects of hydroxyurea on the membrane of erythrocytes and platelets in the sickle cell anaemia. Haematologica. 2004;89:273–280.
   PubMed Web of Science ®Google Scholar
• Hillery CA, Du MC, Wang WC, Scott J P. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. Br J Haematol. 2000;109:322–327.
   PubMed Web of Science ®Google Scholar
• Glover RE, Ivy ED, Orringer EP, Maeda H, Mason R P. Detection of nitrosyl haemoglobin in venous blood in the treatment of sickle cell anaemia with hydroxyurea. Mol Pharmacol. 1999;55:1006–1010.
   PubMed Web of Science ®Google Scholar
• Gladwin MT, Shelhamer JH, Ognibene FP, et al. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br J Haematol. 2002;116:436–444.
   PubMed Web of Science ®Google Scholar
• Charache S, Barton FB, Moore RD, et al. Hydroxyurea and sickle cell anaemia: clinical utility of a myelosuppressive ‘switching’ agent: the multicenter study of hydroxyurea in sickle cell anaemia. Medicine. 1996;75:300–326.
   PubMed Web of Science ®Google Scholar
• Karimi M, Darzi H, Yavarian M. Haematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005;27:380–385.
   PubMed Web of Science ®Google Scholar